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Microglia are patrolling cells that sense changes in the brain microenvironment and
respond acquiring distinct phenotypes that can be either beneficial or detrimental
for brain homeostasis. Anti-inflammatory microglia release soluble factors that might
promote brain repair; however, in glioma, anti-inflammatory microglia dampen immune
response and promote a brain microenvironment that foster tumor growth and invasion.
The chemokine CXCL16 is expressed in the brain, where it is neuroprotective against
brain ischemia, and it has been found to be over-expressed in glioblastoma (GBM).
Considering that CXCL16 specific receptor CXCR6 is diffusely expressed in the brain
including in microglia cells, we wanted to investigate the role of CXCL16 in the modulation
of microglia cell activity and phenotype, and in the progression of glioma. Here we report
that CXCL16 drives microglia polarization toward an anti-inflammatory phenotype, also
restraining microglia polarization toward an inflammatory phenotype upon LPS and IFNγ
stimulation. In the context of glioma, we demonstrate that CXCL16 released by tumor
cells is determinant in promoting glioma associated microglia/macrophages (GAMs)
modulation toward an anti-inflammatory/pro-tumor phenotype, and that cxcr6ko mice,
orthotopically implanted into the brain with GL261 glioma cells,survive longer compared
to wild-type mice. We also describe that CXCL16/CXCR6 signaling acts directly on
mouse glioma cells, as well as human primary GBM cells, promoting tumor cell growth,
migration and invasion. All together these data suggest that CXCL16 signaling could
represent a good target to modulate microglia phenotype in order to restrain inflammation
or to limit glioma progression.
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INTRODUCTION
Modification of local brain microenvironment can be sensed by
microglia cells, which respond to preserve brain homeostasis,
or to exacerbate brain damage. Understanding the mechanisms
of microglia communication in the brain is important to
identify molecular players that can be used as targets to
counteract brain damage and preserve brain homeostasis.
Within the brain, microglia are plastic cells that constantly
monitor brain parenchyma to sense local perturbation and,
depending on specific environmental cues, can change their
phenotype and functional activity promoting inflammatory or
anti-inflammatory conditions (1, 2).
While chemokines were originally discovered for their
ability to regulate leukocyte trafficking, it is now accepted
that, beyond chemotaxis, these molecules exert pleiotropic
activities in the context of brain physiology, as well as
brain cancer (3–8). A crucial role for chemokines and
their receptors as mediators of homeostatic crosstalk between
neurons and glia has emerged (9, 10) and we have recently
shown that the trans-membrane chemokine CXCL16, through
its unique receptor CXCR6, orchestrates cell cross-talk to
promote neuroprotection against glutamate-induced excitotoxic
insults (11); to mediate endogenous protective mechanisms to
counteract neuronal damage during brain ischemia (12); and to
modulate neurotransmitter release in the hippocampus (13).
Glioblastoma (GBM) is a high grade tumor with a
poor prognosis. Despite aggressive surgical resection and
chemotherapy, GBM patients undergo tumor recurrence due
to the highly infiltrative nature of the tumor cells, and to the
persistence of chemotherapy-resistant cells (14). Glioma cells
release molecular regulators, such as cytokines and growth
factors, which may act in autocrine ways promoting tumor cell
proliferation and invasion or in paracrine ways contributing
to the establishment of a pro-tumor-microenvironment
(15–17). Non-tumor cells of the brain parenchyma, such
as astrocytes, endothelial cells, but also microglia, as well
as infiltrating peripheral immune cells, sense glioma, and
contribute to the formation of a tumor niche that provides a
crucial environment for glioma progression. In this context,
the cross-talk between tumor cells and glioma associated
microglia/macrophages (GAMs) leads to GAMs polarization
toward an anti-inflammatory, immunosuppressive, pro-invasive
phenotype that support tumor growth and invasion (18).
GBM cells express chemokines that regulate tumor cell
proliferation, invasion, angiogenesis, as well as the maintenance
of an immunosuppressed microenvironment (19, 20). CXCL16 is
expressed in human glioma (21), while the presence of CXCR6 is
controversial, likely associated with glioma-stem cells (21, 22).
In the present paper we highlight for the first time a major
role of CXCL16/CXCR6 axis in driving microglia polarization
toward an anti-inflammatory phenotype that: in inflammatory
context provides a neuroprotective mechanism to limit brain
damage; in the context of glioma triggers a pro-tumoral
microenvironment. Moreover, we show that CXCL16 produced
by glioma cells directly stimulates the CXCR6 expressed by tumor
cells, promoting their proliferation, migration and invasion.
MATERIALS AND METHODS
Materials
Recombinant murine CXCL16 (cat#250-28) and CXCL12
(cat#250-20A) were from Peprotech; IL-4 (cat#12340045) and
IFNγ (cat#12343536) were from Immunotools; anti-CXCL16
(cat# MAB503-100), mouse CXCR6 PE-conjugated antibody
(cat# FAB2145P−025, RRID:AB_2089531), human CXCR6 PE-
conjugated antibody (cat#FAB699P−025, RRID:AB_2261441)
were from R&D System, APC anti mouse H-2Kb/H-2Db
(cat#114613) and APC anti mouse CD1d antibody (cat#123521,
RRID:AB_2715919) were from Biolegend; APC rat anti-
mouse CD44 (cat# 559250), PE rat anti-mouse CD274
(PD-L1)(cat#558091) were from BD Pharmingen; IgG from
rat serum antibody (cat#l4131, RRID: AB_1163627), LPS
(cat#L4391), 2′,7′-Dichlorofluorescin diacetate (cat#D6883)
were from Sigma-Aldrich; anti-Iba1antibody was from Wako
(cat#019-19741, RRID:AB_839504); anti-GFAP (cat#NB300-
141, RRID:AB_10001722), anti-5-bromo-2-deoxyuridine
(cat#NB500169, RRID:AB_341913) antibodies were from
Novus Biological and anti-Arg1antibody was from Santa Cruz
(cat#sc-271430 RRID:AB_10648473); anti-CD68 antibody
(cat#MCA1957T, RRID:AB_322219) was from AbD Serotec;.
Secondary Abs were from DAKO; Microbeads CD11b+ were
from Miltenyi Biotec; Trans-well inserts were from BD Labware
(cat#353097); IPTG (Dioxane-free) was from Thermo Fisher
(cat#AM9464). Hematoxylin, eosin, and BSA were from Sigma-
Aldrich. All cell culture media, fetal bovine serum (FBS), goat
serum, penicillin G, streptomycin, glutamine, the Thermo Script
RT-PCR System, and Hoechst (cat#33342, RRID:AB_10626776)
were from Invitrogen. 5-Bromo-2′-Deoxyuridine (BrdU)
(cat#B5002) and lentiviral shRNA clones targeting murine
CXCR6 and CXCL16 were from Sigma-Aldrich. Elisa kit for
Interleukin 1 Beta (IL-1β) was from Claude-Clone Corp.
(cat#SEA563Mu); Elisa kit for CXCL16was from RayBiotech
(cat#ELMCXCL16); Griess reagent kit for Nitrite determination
was from Molecular Probe (cat#G-7921), Red fluorescent
FluoSpheres (0.03%) were from Invitrogen.
Ethics Statement
This study was approved: by the Institutional Review Board
of the Policlinico Umberto I Medical Center according to
the Bioethics and Safety Act and the Declaration of Helsinki.
Each participant provided oral informed consent (according
to the principle 22 of Ethical Principles for Medical Research
Involving Human Subjects); by the Institutional Review Board of
Neuromed Medical Center according to the Bioethics and Safety
Act and the Declaration of Helsinki. Each participant provided
written informed consent.
Human Tissue Samples
Tumor specimens (GBM 1, 2, 3, 11, 13, 14, 19, 28, 40, 45, 46,
51, 58) were obtained at Policlinico Umberto I (Rome) and
Neuromed (Pozzilli, Isernia) from adult glioblastoma (GBM).
Within half an hour from surgical resection GBM tissues were
processed to obtain primary GBM cells or frozen for molecular
study. Histopathological typing and tumor grading were done
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according to the WHO criteria resulting as grade IV. Normal
cerebral tissues derived from the prefrontal cortex of patients
who died from heart failure were kindly provided byDr. Eleonora
Aronica, with ethics approval of Amsterdam University.
Animals and Cell Cultures
The experiments described in the present work, were approved
by the Italian Ministry of Health in accordance with the
guidelines on the ethical use of animals from the European
Community Council Directive of September 22, 2010
(2010/63/EU). Wild type mice C57BL/6J (cat# JAX: 000664,
RRID: IMSR_JAX:000664) and Homozygous cxcr6gfp/gfp
knock-in mice (cat# JAX: 005693, RRID: IMSR_JAX:00569)
(23), in which the coding region of CXCR6 receptor has been
substituted with the coding region of the green fluorescent
protein, were from Jackson Laboratory. In the present
manuscript, we refer to cxcr6gfp/gfp knock-in mice as cxcr6ko
mice, and to C57BL/6J as wt mice.
The mouse GL261 glioma cell line (RRID:CVCL_Y003;
kindly provided by Dr. Serena Pellegatta, Istituto Di Ricovero
e Cura a Carattere Scientifico, Besta, Milan) was cultured
in growth medium (DMEM with 20% heat-inactivated FBS,
100 IU/ml penicillin G, 100µg/ml streptomycin, 2.5µg/ml
amphotericin B, 2mM glutamine, and 1mM sodium pyruvate).
GL261/CD133+ cells were obtained as previously described
in Garofalo et al. (24). The cell lines were tested for
mycoplasma contamination (negative). Primary GBM cells were
obtained as previously described (25). Briefly tumor tissues
were mechanically dissociated to cell suspensions and red blood
cells were lysed with hypotonic buffer. Tumor cells were re-
suspended in serum-free growthmedium and cultured at 37◦C in
humidified atmosphere with 5% CO2. Twenty-four hours later,
non-adherent cells were removed and the growth medium was
supplemented with 10% heat-inactivated FBS. Cells were sub-
cultured when confluent. In the current study, primary GBM
cells, were used within 1–3 passages, and were named GBM13,
GBM19, GBM40, and GBM45.
Microglia Culture and Polarization
Microglia cells were obtained from mixed glia cultures derived
from the cerebral cortices of post-natal day 0–2 (p0–p2) wt
mice. Cortices were chopped and digested in 15 U/ml papain for
20min at 37◦C. Cell suspensions were plated (5× 105 cells/cm2)
on poly-L-lysine (0.1 mg/ml) coated flasks in growth medium
supplemented with 10% FBS. After 9–11 days, cultures were
shaken for 2 h at 37◦C to detach and collect microglia cells.
These procedures gave almost pure microglial cell populations
as previously described (26). For microglia polarization, cells
were seeded on poly-L-lysine (cat#P2636 from Sigma-Aldrich)
coated six-well plate and the day after they were treated with
LPS 100 ng/ml + IFNγ 20 ng/ml or glioma conditioned medium
(GCM) with rat AbCXCL16 or IgG (1µg/ml) for 24 h.
CXCR6 and CXCL16 Silencing by shRNA
Interference
GL261 cells were transduced by lentiviral particles directing
IPTG-inducible expression of CXCR6 shRNA or constitutive
expression of CXCL16 shRNA constructs. Cells (1.6 × 104) were
plated in 96-well plates and infected for 24 h according to the
manufacturer’s instructions. Transduced cells were selected with
2µg/ml puromycin for 3–12 days. IPTG (5mM) was added for
10 days to culture medium to induce CXCR6 shRNA expression.
Knockdown efficiency of CXCR6 receptor and CXCL16 was
evaluated by PCR or chemotaxis assay. Silenced cell lines were
named GL261shCXCR6 and GL261shCXCL16 in this study.
Chemotaxis and Invasion in vitro Assays
GL261, GL261shCXCR6 and human primary GBM cells
were pre-incubated in chemotaxis medium (DMEM without
glutamine, 100 IU/ml penicillin G, 100µg/ml streptomycin, 0.1%
BSA, and 25mM HEPES, pH 7.4) with AraC (10µM, 15min) to
block cell duplication. Cells (4 × 104) were plated in the upper
wells of 48-well boyden chamber (NeuroProbe) on 8 µm-pored
Poly-L-Lysine coated membrane. The lower wells contained
CXCL16 (0.1, 1, 10, 50, or 100 nM), CXCL12 (50 ng/ml), or
vehicle (C). Cells were left migrate for 4 h (GBM cells) or 24 h
(GL261). For invasion assay, GL261 and GBM19 were plated at a
density of 2× 104 cells/cm2 on matrigel-coated transwells (8µm
pored membrane) and left invade toward CXCL16 (1, 10 nM) or
vehicle, respectively, for 48 or 24 h at 37◦C. Migrated/invaded
cells were fixed and stained with a solution containing 50%
isopropanol, 1% formic acid, and 0.5% (w/v) brilliant blue R 250.
For eachmembrane, stained cells were counted in at least 20 fields
with a 32× objective of a phase-contrast microscope (Zeiss).
MTT Assay
GL261, GL261shCXCR6, and GBM19 cells were seeded into 96
well plates (5× 103) and treated with vehicle (C) or with CXCL16
(10 nM) for different time points (0, 24, 48, 72, or 96 h). MTT
solution (500µg/ml) was added into each well for 1.5 h. DMSO
was then added to stop the reaction and the formazan produced
was measured at 570 nm. Viability of cells was expressed relative
to absorbance values.
Western-Blot
For protein analysis, microglial cells (6× 105) were seeded on six-
well plates and treated with vehicle, CXCL16 (200 nM), glioma
conditioned medium (GCM) with or without rat AbCXCL16 for
24 h; cells were washed with PBS and lysed in hot 2 × Laemmli
buffer, boiled 5min, and sonicated. The same amount of proteins
was separated on 12% SDS-polyacrylamide gel and analyzed by
Western immunoblot using the following primary antibodies:
ARG-1 1:200, ACTIN 1:2,000. HRP-tagged goat anti-mouse
and anti-rabbit-IgG were used as secondary antibodies (1:2,000;
Dako), and detection was performed by the chemiluminescent
assay Immun-Star WesternC Kit (Bio-Rad, CA). Densitometric
analysis has been carried out withQuantity One software (Biorad,
CA).
Phagocytosis Assay
Microglial cells were seeded on poly-L-lysine-treated 10mm glass
coverslips (7 × 104 cells) and stimulated with CXCL16 (200 nM)
or vehicle for 24 h and GCM with or without rat AbCXCL16
for 24 h. Medium was then removed, 0.05% (corresponding to
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1.8 × 107 spheres/ml) red fluorescent FluoSpheres were added
for 1 h in serum-free medium (0.1% BSA), and nuclei were
stained by Hoechst. Cells were washed three times with PBS
to remove non-phagocytized spheres and fixed in 4% PFA for
1min. Phagocytosis was quantified by counting the number of
phagocytizing cells (scoring as positive only cells with at least
five FluoSpheres to avoid possible false positives due to sphere
adhesion to cell surface) in at least 20 random fields per coverslip.
Form Factor Calculation
Microglia were seeded on glass coverslips, treated as necessary,
fixed, permeabilized, blocked and stained with Alexa-Fluor
488 Phalloidin (Invitrogen) for 20min together with Hoechst.
Fluorescent images were processed using the MetaMorph 7.6.5.0
software (Molecular Device, Sunnyvale, CA, USA), and form
factor was calculated according the formula: 4pi area/perimeter2
(27). Form factor is a parameter taken as 1 for round cells, and
correspondingly <1 when the morphology deviates from the
spherical shape.
Nitric Oxide (NO) Measurement
NO production by microglia cultures was assessed by measuring
nitrite accumulation in the culture medium by Griess Reagent
Kit according to manufacturer’s instructions (Molecular Probes,
MA, USA). The absorbance was measured at 570 nm in a
spectrophotometer microplate reader (BioTek Instruments Inc.,
VT, USA).
ELISA Assay
Microglial cells (6 × 105 cells) were seeded onto a 6-well culture
plate, after 24 h cells were stimulated with LPS 100 ng/ml +
IFNγ 20 ng/ml or LPS 100 ng/ml + IFNγ 20 ng/ml + CXCL16
(200 nM) for 24 h. Medium was than collected, centrifuged at
1,000 × g for 20min, and supernatant was stored at −80◦C.
Control cells were stimulated only with vehicle. IL-1β present in
the supernatant was measured using a specific ELISA for mouse
IL-1β (Cloud-Clone Corp.) as described by themanufacturer. For
each sample, cells were detached and proteins were quantified
(BCA assay). For quantification of mouse CXCL16 in glioma
conditioned medium (GCM) we used the mouse CXCL16
ELISA Kit (RayBiotech, Norcross, GA, USA) as described by
the manufacturer. All supernatants were centrifuged (1,000
× g for 5min) to eliminate floating cells and then samples
were 10-fold concentrated with 10 KDa Microcon Centrifugal
Filter devices (Merck Millipore, Darmstadt, Germany). Samples
were measured in duplicate and confirmed in two independent
experiments.
Reactive Oxygen Species (ROS)
Measurement
Primary microglia cultures (3 × 105 cells) were treated for 18 h
with 200 nM CXCL16 and then cells were incubated with 20µM
of 2′,7′-Dichlorodihydrofluorescein diacetate (DCF-DA, Sigma-
Aldrich, #D6883) for 30min at 37◦C. Cell fluorescence was
detected in FL1 channel and analyzed with a FACSCanto II (BD
Biosciences). Data were elaborated using FlowJo v9.3.2 software
(TreeStar, Ashland, OR, USA).
Cytofluorimetric Analysis
Cells were harvested in PBS with 5mM EDTA and washed in
staining buffer (PBS without Ca2+ Mg2+, 0.5% BSA, 2mM
EDTA, 0.025% NaN3). mAbs directly conjugated to PE and APC
fluorochromes and specific for the following antigens were used:
MHC class I (APC anti-mouse H-2Kb/H-2Db, BioLegend), CD1
(APC anti-mouse CD1d, clone 1B1, BioLegend), CD44(APC rat
anti-mouse CD44, clone IM7, BD Pharmingen), PD-L1 (BD
Pharmingen), CXCR6 (R & D systems). Corresponding isotypes
were used for negative control. Immunostaining was performed
with saturating amounts of Abs for 30min at 4◦C. Samples were
acquired with a flow cytometer FACSCanto II (BD Biosciences)
and data were elaborated using FlowJo 9.3.2 software (TreeStar).
Reverse Transcript PCR (RT-PCR) and
Quantitative Real Time PCR (RT-qPCR)
Samples were lysed in TRYzol reagent for isolation of total RNA.
The quality and yield of RNAs were verified using NANODROP
One (Thermo Scientific). For RT-PCR one microgram of total
RNA was reverse transcribed using ThermoScript RT-PCR
System and 150 ng of the reverse transcription products were
used as a template for PCR amplification. The PCR protocol was
as follows: 95◦C for 5′, 30 cycles 94◦C for 30′′, 55◦C for 30′′,
and 72◦C for 30′′. MJ Mini Thermal Cycler (Bio-Rad) was used
for all reactions and amplification products were analyzed on
1.8% agarose gel stained with ethidium bromide. For RT-qPCR
Reverse transcription reaction was performed in a thermocycler
using IScript TM RT Supermix (Biorad) under the following
conditions: incubation, 25◦C, 5′; reverse transcription, 42◦C, 45′;
inactivation, 85◦C, 5′. Real Time-PCR was carried out in a I-
Cycler IQ Multicolor RT-PCR Detection System using Sso Fast
Eva Green Supermix (Biorad). The PCR protocol consisted of 40
cycles at 95◦C, 30′′ and 60◦C, 30′′. For quantification analysis,
the comparative Threshold Cycle (Ct) method was used. The
Ct values from each gene were normalized to the Ct value of
GAPDH in the same cDNA samples. Relative quantification was
performed using the 2−11Ct Ct method (28) and expressed
as fold increase in arbitrary values. Primers sequences are
reported in Supplementary Table 1. Primers used for CXCR6
and CXCL16 were not intron spanning, and “no-RT” reactions
were used as controls to rule out priming off of genomics DNA.
As control for cxcl16 and cxcr6 mRNA expression, we used RNA
from Human fibroblast cell line HFF-1 (ATCC R© SCRC-1041TM,
RRID:CVCL_3285); RNAs from Mouse fibroblast NIH/3T3 cells
(ATCC R© CRL-1658TM, RRID:CVCL_0594); RNA from primary
human T lymphocytes kindly provided by Dr. Samantha Cialfi,
Department of Molecular Medicine, Sapienza, Rome); RNA from
mouse primary CD4+ T cells derived from spleen.
Brain Injection of Glioma Cells and Survival
Analysis
Eight week old male mice (wt or cxcr6ko) were anesthetized
with chloral hydrate (400 mg/kg, i.p.) and placed in a stereotaxic
head frame. Animals were injected with 1 × 105 GL261,
GL261shCXCR6, or GL261shCXCL16 cells at 2mm lateral
and 1mm anterior to the bregma in the right striatum. Cell
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suspensions, in sterile phosphate-buffered saline (PBS) (5 µl)
were injected with a Hamilton syringe at a rate of 1 µl/min
at 3mm depth. For GL261 shCXCR6, after 10 days of IPTG
treatment, cells were injected in mice and shRNA expression
was maintained by adding IPTG (10mM) in drinking water.
For survival analysis glioma injected mice were daily monitored.
The end points were determined by lack of physical activity or
20% weight loss in glioma-bearing mice. The mean survival time
was calculated using the Kaplan–Meier method and statistical
analysis was performed using a log-rank test.
Tumor Volume Evaluation and Brain
Sections Immunostaining
Seventeen days after tumor cell injection glioma-bearing mice
were killed and brains were isolated and fixed in 4% buffered
paraformaldehyde. Brains were snap frozen and cut in 20µm
coronal brain cryosections. Tumor volume was evaluated with
hematoxylin–eosin staining as previously described. Briefly, after
staining, brain slices (20µm of thickness) were analyzed by the
Image Tool 3.0 software (University of Texas, Health Science
Center, San Antonio, TX, USA). Tumor volume was calculated
according to the formula (volume = t×ΣA), where A = tumor
area/slice and t = thickness (29). For tumor cell proliferation
in vivo, 17 days after tumor cells injection glioma-bearing
mice were injected intraperitoneally with bromo-2-deoxyuridine
(50 mg/kg). Two hours later, mice were killed and brains
processed for BrdU immunostaining. For immunostaing analysis
cryosections were washed in PBS and blocked with blocking
solution (3% goat serum, 0.3% Triton X-100 in PBS) for 1 h at
room temperature. Sections were then incubated with specific
antibodies (anti-Iba1 1:500, anti-CD68 1:200, anti-GFAP 1:750,
anti-BrdU 1:200) in 1% goat serum and 0.1% Triton X-100/PBS
solution overnight at 4◦C. After several washes, sections were
stained with the respective secondary fluorophore-conjugated
antibody and Hoechst for nuclei visualization. For Iba1 staining,
citrate buffer antigen retrieval protocol was used. For BrdU
immunostaining, sections were pretreated with HCl 1N for
15min, HCl 2N for 25min at 37◦C, and neutralized with 0.1M
borate buffer. Digitized fluorescent cell images were collected
using an inverted fluorescence microscope (Nikon Ti Eclipse)
and analyzed with MetaMorph analysis software (Molecular
Devices, USA).
BrdU Cell Immunostaining
GL261 cells were grown on glass coverslips at a density of 5× 104
cells/cm2 and treated for 4 h with CXCL16 10 nM or vehicle. Cells
were then incubated with 10µg/ml BrdU for 30min, washed
with PBS and fixed in 4% paraformaldehyde for 20min. Fixed
cells underwent immunostaining protocols as described for brain
sections. Hoechst was used for nuclear staining. BrdU positive
cells were counted out of 800 cells for condition.
Invasion in vivo Assay
Seventeen days after GL261 injection, mice brains were isolated
and fixed in 4% buffered formaldehyde for morphological
evaluation. Coronal brain sections (20µm), prepared using the
standard procedures, were stained with hematoxylin and eosin.
For analysis of tumor invasiveness, glioma cells protruding more
than 150µm from the main tumor mass were counted in at least
20 fields, obtained from six slices per mice.
Isolation of CD11b+ Cells
Glioma-bearing wt or cxcr6ko mice after 17 days from
inoculation were deeply anesthetized and intracardially perfused
with ice cold PBS. Brains were removed, cut into small pieces and
single-cell suspensions were achieved by enzymatic digestion in
trypsin (0.25 mg/ml) solution in Hank’s balanced salt solution
(HBSS). Cell suspensions were labeled with CD11b+Microbeads,
loaded onto a MACS Column (MiltenyiBiotec) and placed in
the magnetic field of a MACS Separator. After removing the
magnetic field, CD11b+ cells were eluted and used for RNA
extraction. CD11b+ cells were also isolated from human GBM
tissues surgically removed from patients as described above.
Statistical Data Analysis
Data are expressed as the mean ± SEM. Statistical significance
was assessed by Student’s t-test, Student’s paired t-test or one-
way ANOVA, as indicated; Holm–Sidak, Turkey post-hoc test or
Student-Newman-Keuls Method were used as a post-hoc test. For
Kaplan–Meier analysis of survival, the log-rank test was used. All
statistical analyses were done using Sigma Plot 11.0 software.
RESULTS
CXCL16 Drives Microglia Polarization
in vitro
Since we have shown that CXCL16 is neuroprotective in ischemia
(11, 12), and neuroinflammation plays a role in brain damage
following ischemic insult (30, 31), we considered the possibility
that CXCL16, acting on CXCR6 expressed by microglia cells
(11), might provide protective effects also modulating microglia
phenotype.
We performed in vitro experiments treating primary mouse
microglia for 24 h with CXCL16 (200 nM) and analyzing the
expression of pro- (nos2, il1b, cd86, tnfa) and anti- (arg1,
chil3, retnla, cd163) inflammatory genes (32) by RT-qPCR: as
reported in Figure 1A, CXCL16 increases the expression of anti-
inflammatory genes (right panel; n = 5 p < 0.05; Student’s
t-test), while no significant modulation of pro-inflammatory
genes is observed, with the exception of nos2 (left panel; n = 5
p < 0.05; Student’s t-test).The ability of CXCL16 to induce anti-
inflammatory polarization was further supported by an increase
in ARG-1 protein expression in microglia treated with CXCL16
(200 nM, 24 h) vs. not treated cells (n = 4, p < 0.05; Student’s
t-test), Figure 1B. Moreover, CXCL16 increases: the number
of phagocytizing microglia (measured as number of cells that
phagocytized five or more fluorescence beads) (n = 3, p < 0.001;
Student’s t-test) vs. control, Figure 1C; the production of reactive
oxygen species (measured as generated DCF fluorescence) vs.
vehicle (n = 3 experiments in duplicates, p < 0.05; Student’s
t-test), Figure 1D.
We then wanted to verify the hypothesis that CXCL16 could
also modulate microglia polarization in the context of pro-
inflammatory conditions (LPS, 100 ng/ml + IFNγ, 20 ng/ml,
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FIGURE 1 | Effects of CXCL16 in modulating microglia phenotype. Expression analysis by RT-qPCR for mRNAs of pro-inflammatory (nos2, il1b, cd86, tnfa) or
anti-inflammatory (arg1, chil3, retnla, cd163) related genes in primary wt microglia treated with: (A) vehicle or CXCL16 (200 nM); (E) LPS+IFNγ (pro-inflammatory
(Continued)
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FIGURE 1 | stimulus) in the absence or presence of CXCL16. For each gene data are expressed as specific mRNA fold increase in CXCL16 treated cells normalized
to specific mRNA expression in vehicle (A), or in LPS + IFNγ treated cells (D); (B) Western-blot analysis of ARG-1 protein expression in microglia cells incubated
vehicle or CXCL16. Right, representative image; left histogram bar of the quantification of ARG-1 expression (data are expressed as ARG-1 signal normalized to
ACTIN signal). (C) Phagocytosis of fluorescent beads in microglia cells stimulated with CXCL16 (200 nM, 24 h), or not (vehicle). Data are expressed as number of cells
containing 5 or more beads (gray bars) within total counted cells (white bars); (D) ROS production of microglia cells after CXCL16 treatment as evaluated by using the
DCF probe. DCF was analyzed as median fluorescence intensity (MFI) by flow cytometry; (F,G) Release of NO and IL-1β by microglia cells not stimulated (vehicle) or
stimulated with LPS + IFNγ in the absence or presence of CXCL16; for IL-1β data are expresses as fold increase vs. vehicle; (H) Form factor analysis of microglia cells
treated with IL-4 (anti-inflammatory stimulus), LPS + IFNγ, LPS + IFNγ + CXCL16, or CXCL16. Statistical analysis: Data are expressed as the mean (± s.e.m.)
(A) n = 4, *p < 0.05, Student’s t-test; (E) n = 5, *p < 0.05, Student’s t-test. For each gene, variability in its expression among control conditions in different
experiments never exceeded 10%. (B) n = 4, *p < 0.05, Student’s t-test; (C) n = 3, **p < 0.001, Student’s t-test; (D) n = 3 experiments in duplicates, *p < 0.05,
Student’s t-test; (F) n = 7, *p < 0.05, one-way ANOVA followed by Holm–Sidak post-hoc test; (G) n = 4, *p < 0.05, one-way ANOVA followed by Holm–Sidak
post-hoc test; (H) n = 30 cells,*p < 0.05, one-way ANOVA followed by Tukey post-hoc test.
24 h): as reported in Figure 1E, the presence of CXCL16 (200 nM)
significantly reduced the expression of nos2, il1b, and tnfa genes
(n = 4–5, p < 0.05; Student’s t-test). Moreover, we measured the
release of nitric oxide (NO) and IL-1β by microglia cells treated
with vehicle or LPS + IFNγ, in the presence or not of CXCL16:
as shown in Figures 1F,G, the release of NO (n = 7, p < 0.05;
One-way ANOVA followed by Holm–Sidak post-hoc test) and IL-
1β (n = 4, p < 0.05; One-way ANOVA followed by Holm–Sidak
post-hoc test) induced by LPS + IFNγ was significantly reduced
by treatment with CXCL16.
The activation state ofmicroglia cells has been often correlated
with their shape, although it is not possible to strictly associate
a morphology to a specific phenotype (33). We measured the
ramification grade of microglia calculating the “form factor,”
a parameter taken as 1 for round cells, and correspondingly
<1 when the morphology deviates from the spherical shape.
As shown in Figure 1H, in analogy with what previously
reported (29), the form factor of cells polarized toward an
anti-inflammatory ramified phenotype (IL-4 20 ng/ml, 24 h) was
0.26 ± 0.03, while in cells with an inflammatory phenotype
(LPS+IFNy) was 0.66± 0.04. The form factor of cells stimulated
with CXCL16 (0.37 ± 0.03) or treated with LPS + IFNy +
CXCL16 (0.37± 0.04) were similar to cells treated with IL-4, and
statistically different from those treated with LPS+ IFNy (n= 30
cells in three different experiments, p < 0.05; One-way ANOVA
followed by Tukey post-hoc test), further confirming that
CXCL16 polarizes cells toward an anti-inflammatory phenotype.
CXCL16 Released by Glioma Promotes
Microglia Polarization Toward an
Anti-Inflammatory Phenotype in vitro
We analyzed the expression of CXCL16 and CXCR6 in human
GBM tissues acutely (<2 h) removed from patients, and in
normal cerebral tissues (controls) derived from the temporal
and frontal cortex of patients who died for heart failure:
RT-qPCR analysis revealed a significant higher expression for
cxcl16 and cxcr6 mRNAs in GBM, compared to controls
(Figure 2A left panel) (p < 0.001 and p < 0.05, respectively;
Student’s t-test). We also analyzed the expression of cxcr6 in
human CD11b+ cells (microglia/macrophages) isolated from
GBM tissues, and found a considerable expression of cxcr6
also in these cells (Figure 2A, right panel). To study the
role of CXCL16/CXCR6 in glioma development in a mouse
model, we analyzed cxcl16 and cxcr6 mRNAs expression in
GL261, and in the more aggressive derived glioma stem cells
(GL261/cd133+ cells): as shown in Figure 2B, both chemokine
and its receptor are expressed by GL261 cells, with higher
expression of cxcr6 in GL261/cd133+ cells (both by RT-
PCR and RT-qPCR analysis). Mouse T-cells and fibroblasts
were analyzed as positive controls for cxcr6 and cxcl16
mRNAs expression, respectively. Furthermore, we analyzed the
expression of CXCR6 membrane protein by flow cytometry,
using a mouse CXCR6 PE-conjugated antibody and confirmed
the expression of CXCR6 on GL261 cells (Figure 2B, right
panel).
It is known that glioma cells secrete soluble factors
that contribute to the establishment of a pro-tumor
microenvironment switching GAMs toward an anti-
inflammatory phenotype (2, 32, 34); thus, considering that
microglia cells do express CXCR6, we speculated that CXCL16
released by tumor cells might act as an effector in driving such
microglia polarization.
Primary microglia cells were incubated for 24 h with glioma
conditioned medium (GCM) in the presence of neutralizing
anti-CXCL16 antibody (AbCXCL16) (GCM + AbCXCL16), or
control IgG (GCM + IgG), and analyzed for the expression of
pro- or anti-inflammatory genes. In the presence of AbCXCL16,
microglia increases the expression of nos2, il1b, cd86, tnfa
(pro-inflammatory genes, Figure 2C, left panel), and decreases
the expression of arg1, chil3, retnla, cd163 (anti-inflammatory
genes, Figure 2C, right panel) compared to cells treated with
GCM+IgG (n = 14, p < 0.05; Student’s t-test). As control,
in each experiment we checked the expression of pro- and
anti-inflammatory genes of GCM-incubated microglia (data
not shown). These results suggest that CXCL16 in GCM is
determinant to promote microglia polarization to establish
a pro-tumor/anti-inflammatory microenvironment. To further
support these data we analyzed the phagocytizing activity of
microglia cells incubated with GCM or GCM + AbCXCL16
(Figure 2D), and the expression of ARG-1 in these cells
(Figure 2E): we found a significant reduction in the number of
phagocytizing cells (n= 4, p< 0.001; Student’s paired t-test) and
in the expression of ARG-1 protein (n = 3, p < 0.05; Student’s t-
test) in cells treated with GCM+AbCXCL16 vs. cells treated with
GCM. The presence of soluble CXCL16 in GL261 conditioned
medium was also confirmed by ELISAmeasurement (0.47± 0.03
pg/ml).
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FIGURE 2 | CXCL16 released by glioma cells modulates microglia phenotype. (A) Left panel, RT-qPCR for cxcl16 and cxcr6 (black and white circles) mRNA
expression in human GBM tissues and in human control tissues (temporal or frontal cortex); right panel, qRT-PCR for cxcr6 mRNA expression in human CD11b+ cells
(microglia/machrophages) isolated by GBM tissues. Mean values of double measurements from individual patients; 1CT values = CT gene of interest—CT gapdh
(housekeeping gene). A 1CT of 3.33 corresponds to one magnitude lower gene expression compared to gapdh; (B) Left panel, representative PCR for cxcl16, cxcr6,
and actin mRNAs expression in mouse GL261 cells and mouse GL261 derived stem cells (cd133+); right panel RT-qPCR for cxcl16 and cxcr6 (black and white
circles) mRNAs expression in GL261, cd133+ cells, and in mouse T-cells and fibroblasts; CXCR6 surface expression on mouse GL261 cells as evaluated by flow
cytometry. Black and gray lines represent CXCR6 staining and isotype control, respectively. (C) Expression analysis by RT-qPCR for mRNAs of pro-inflammatory
related genes (nos2, il1b, cd86, tnfa) (left panel), or anti-inflammatory related genes (arg1, chil3, retnla, cd163) (right panel) in primary wt microglia treated with GCM in
the presence of AbCXCL16 neutralizing antibody (GCM + AbCXCL16) or control IgG (GCM + IgG). For each gene data are expressed as specific mRNA fold change
(Continued)
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FIGURE 2 | in GCM + AbCXCL16 treated cells normalized to specific mRNA expression in GCM + IgG treated cells and are the mean (± s.e.m.); (D) Phagocytosis of
fluorescent beads in microglia cells stimulated with GCM or GCM + AbCXCL16. Data are expressed as number of cells containing 5 or more beads (black/gray bars)
within total counted cells (white bars); (E) Western-blot analysis of ARG-1 protein expression in microglia cells incubated with GCM or GCM + AbCXCL16. Top
representative image; bottom histogram bar of the quantification of ARG-1 expression (data are expressed as ARG-1 signal normalized to ACTIN signal). Statistical
analysis: data are expressed as the mean (± s.e.m.) (A) **p < 0.001 cxcl16 expression, #p < 0.05 cxcr6 expression, Student’s t-test; (C) n = 14, *p < 0.05,
Student’s t-test; for each gene, variability in its expression between control conditions in different experiments never exceeded 10%; (D) n = 4, **p < 0.001, Student’s
paired t-test; (E) n = 3, *p < 0.05, Student’s t-test.
CXCR6 Expression in Glioma Recipient
Mice Is Determinant for Tumor
Microenvironment
Since tumor micro-environment plays an important role in
glioma progression, and considering the ability of CXCL16 to
promote microglia anti-inflammatory phenotype in vitro, we
decided to investigate the effect of CXCL16/CXCR6 signaling on
tumor micro-environment in vivo: we therefore orthotopically
implanted GL261 cells into the brain of wt and cxcr6ko mice.
Some animals were used for a survival-analysis, others were
sacrificed 17 days after implantation for tumor volume analysis
(Figure 3A). As reported in Figure 3B, tumor volume was
strongly reduced (62%) in cxcr6ko mice compared to wt mice
(cxcr6ko: 3.83 ± 0.67 mm3; wt: 10.07 ± 0.55 mm3; n = 7–12,
p < 0.001; Student’s t-test). Moreover, survival studies (Kaplan–
Meier analysis) revealed that cxcr6ko mice survive longer than
wt mice (cxcr6ko: 45 ± 2.9 days; wt: 22.8 ± 2.3 days, n = 6–
10; p < 0.001 Log rank test, Figure 3C). These data suggest that
the CXCL16/CXCR6 axis plays a key role in establishing a pro-
tumoral microenvironment in the brain of glioma-bearing mice.
Due to the importance of GAMs in glioma progression, we also
investigated Iba1 and CD68 cell immuno-reactivity. As shown in
Figure 3D there was no difference in Iba1+cells (measured as %
of Iba+ staining per tumor area) inwt and cxcr6komice (cxcr6ko:
0.69± 0.02%; wt: 0.72± 0.04%; n= 4, p= 0.56; Student’s t-test),
but there was a strong reduction in CD68+cells (measured as %
of CD68+ staining per tumor area) in cxcr6komice compared to
wtmice (53% reduction, cxcr6ko: 0.26± 0.02%;wt: 0.55± 0.02%;
n = 4, p < 0.05; Student’s t-test), indicating that although there
was no difference in the recruitment of total GAMs in tumor
mass, they were differently activated in cxcr6komice.
To confirm a role of CXCL16 in driving GAMs toward a pro-
tumor phenotype in vivo, we implanted GL261 cells into the
brain of wt and cxcr6ko mice and, after 17 days, CD11b+ cells
were isolated from the ipsi- and contra-lateral brain hemispheres
of each mice and analyzed by RT-qPCR. Data reported in
Figure 3E show no significant differences in the expression levels
of pro-inflammatory genes (n= 4–5, p > 0.05; Student’s t-test);
instead we found a significant reduction in the expression of
anti-inflammatory genes such as arg1, chil3, retnla, cd163 in
CD11b+ cells from cxcr6ko mice (Figure 3F; n = 4–5, p < 0.05;
Student’s t-test). In order to look at differences in the brain
tumor microenvironment in the two genotypes, we also analyzed
astrocytic activation and tumor cells invasion in the surrounding
brain tissue.
As reported in Figure 3G (left), the brain of glioma-bearing
cxcr6ko mice showed reduced astrogliosis (measured as % of
GFAP+ area in brain slice) compared to wtmice (46% reduction,
0.53 ± 0.03% in wt, 0.29 ± 0.03% in cxcr6ko; n = 4, p < 0.001;
Student’s t-test). In addition, as revealed by the analysis of the
number of glioma cells protruding more than 150µm from the
main tumor mass, cxcr6ko mice presented a reduction in the
number of glioma cells invading the brain parenchyma (10.1 ±
1.0 cells for brain slice) compared to wt mice (24.8± 1.5 cells for
brain slice) (n= 3, p< 0.05; Student’s t-test), Figure 3G (right).
Direct Effects of CXCL16/CXCR6 Axis on
Glioma Cells
We investigated the direct effects of CXCR6 stimulation on
GL261 cells: at this aim cells were stimulated with CXCL16
and analyzed for migration in the Boyden chamber assay.
Data reported in Figure 4A (left panel) demonstrate that the
chemotactic index of GL261 increased with CXCL16 dose,
starting at 0.1 nM CXCL16, with maximal effect at 10 nM
(n = 3 experiments in triplicate, p < 0.05; One-way ANOVA
followed by Holm–Sidak post-hoc test). In vitromatrigel invasion
assay with GL261 shows significant increase of cell invasion
upon CXCL16 stimulation (Figure 4A, central panel; n = 3,
p < 0.05; One-way ANOVA followed by Holm–Sidak post-
hoc test). In accordance with this effect, we also found that
CXCL16 stimulation increased the expression level of the matrix
metalloproteinases mmp9 and mmp2 (Figure 4A right panel;
n = 6, p < 0.05; Student’s t-test), whose activity is reported
to be involved with the invasion ability of glioma cells (35).
To investigate whether CXCL16 might directly promote glioma
cell proliferation, in analogy with CXCL12 (20), we analyzed
GL261 proliferation upon stimulation with CXCL16. Figure 4B
shows that CXCL16 (10 nM) significantly increased GL261 cell
number after 24 and 48 h, as revealed by MTT analysis (left
panel; n = 3 experiments in six-replicates, p < 0.05; One way
ANOVA followed by Student-Newman-Keuls Method). Similar
results were obtained measuring BrdU incorporation in GL261
cells: CXCL16 administration (10 nM, 4 h) increased the number
of proliferating BrdU+ cells compared to vehicle (C) stimulated
cells (middle and right panels; n= 3, p< 0.05; Student’s t-test).
CXCR6 Silencing in GL261 Reduces Tumor
Migration and Proliferation in vitro and
in vivo
To confirm the role of CXCR6 activation on glioma cells,
GL261 cells were engineered for CXCR6 silencing, using an
IPTG-inducible shCXCR6 construct. As shown in Figure 4C,
we selected a GL261shCXCR6-inducible cell clone that, after
10 days of treatment with IPTG, presented a strong reduction
in CXCR6 mRNA expression compared to control cells (not
treated with IPTG). To further confirm CXCR6 silencing in the
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FIGURE 3 | CXCL16/CXCR6 axis is involved in establishing a pro-tumor microenvironment. (A) Representative scheme of GL261 transplantation in wt and cxcr6ko
mice; (B) bar histogram of the mean (± s.e.m.) of tumor volume in wt and cxcr6ko mice, and representative hematoxylin-eosin stained coronal brain sections of GL261
(Continued)
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FIGURE 3 | bearing mice; (C) Kaplan–Meier survival curves of wt and cxcr6ko GL261 bearing mice; (D) Immunofluorescence analysis of Iba1 and CD68 expression in
tumor bearing brain slice 17 days after GL261 transplantation in wt and cxcr6ko mice: (central panels) representative immune-fluorescence images for Iba1+, CD68+
(red signals), nuclei are evidenced with Hoechst (blue signal), scale bar = 20µm; (left and right panels): bar histograms representative of the immunofluorescence
analysis of Iba1+, CD68+. Data are expressed as % of Iba+ or CD68+ staining per tumor area; (E,F) RT-qPCR for pro-inflammatory and anti-inflammatory genes in
CD11b+ cells isolated from the ipsilateral and controlateral brain hemispheres of wt and cxcr6ko mice transplanted with GL261 cells. Data are expressed as mRNA
fold increase in the ipsilateral hemisphere vs. the controlateral hemisphere, normalized for gapdh mRNA, and are represented as the mean (± s.e.m.); (G) Left, bar
histogram representative of immunofluorescence analysis of GFAP+ positive cells in tumor bearing brain slice (data are expressed as % of GFAP+ area in brain slice),
and representative images of GFAP+ staining (red signal); right, analysis of glioma cell invasion of surrounding brain tissue in cxcr6ko or wt mice injected with
GL261.Representative coronal brain sections stained with hematoxylin/eosin. Black arrows indicate glioma cells invading the brain parenchyma beyond the main
tumor border (dashed line) for more than 150µm (scale bars, 20µm) and bar histogram of the number of invading tumor cells 17 days after glioma cell
transplantation. Statistical analysis: Data are expressed as the mean number (± s.e.m.) (B) n = 7–12, **p < 0.001, Student’s t-test; (C) n = 6–10, **p < 0.001,
long-rank test; (D) n = 4, *p < 0.05, Student’s t-test; (E,F) n = 4–5, *p < 0.05, Student’s t-test. (G) n = 3–4, **p < 0.001, *p < 0.05, Student’s t-test.
selected clone, we performed chemotaxis experiments toward
CXCL16: Figure 4D shows that shCXCR6 cells (+IPTG) did not
respond to CXCL16 (n = 4 experiments in duplicate, p < 0.05;
Two- way ANOVA followed by Holm–Sidak post-hoc test).
Since CXCL16 is present in GCM and CXCL16 stimulation
increases GL261 proliferation (Figure 4B), we speculated that
basal cell proliferation might be altered in shCXCR6 cells: as
reported in Figure 4E, cell proliferation measured at 24, 48,
72, 96 h was reduced in IPTG induced GL261shCXCR6 cells
(+IPTG) compared to GL261shCXCR6 not treated cells (-IPTG)
(n= 4 experiments in quadruplicate, p< 0.05;One way ANOVA
followed by Student-Newman-Keuls Method).
To confirm a role for CXCR6 in glioma development also in
vivo, we orthotopically implanted GL261shCXCR6 cells, silenced
or not with IPTG (+/-IPTG), into the brain of wt mice.
Tumor-bearing mice were supplied with drinking water with or
without IPTG, respectively, and, 17 days after implantation, were
sacrificed for tumor volume analysis (Figure 4F). Mice injected
with tumor cells silenced for CXCR6 revealed a significant
reduction (67%) in tumor volume compared to mice injected
with GL261 expressing CXCR6 (2.19 ± 0.47 mm3 shCXCR6
+ IPTG mice vs. 6.54 ± 1.26 mm3 shCXCR6–IPTG) (n = 5,
p < 0.05; Student’s t-test). These mice were also i.p. injected
with BrdU 4 h before sacrifice, in order to analyze tumor cell
proliferation in vivo: as shown in Figure 4G, shCXCR6+ IPTG
cells revealed a significant reduction in BrdU incorporation (0.52
± 0.08% of tumor area) compared to control cells (0.81 ± 0.05%
of tumor area) (n = 3, p < 0.05; Student’s t-test). Moreover, as
reported in Figure 4H, in mice injected with tumor cells silenced
for CXCR6 there was a reduced number of glioma cells that
migrate and invade the surrounding brain tissue (15.00± 1.8 cells
for brain slice) compared to mice injected with cells not silenced
(28.6 ± 3.9 cells for brain slice) (n = 3–4, p < 0.05; Student’s
t-test).
CXCL16 Released From Glioma Plays a
Role in Tumor Development in vivo
To prove a role of CXCL16 released from glioma cells in
tumor progression, GL261 cells were engineered for constitutive
CXCL16 silencing, using shCXCL16 construct. As shown in
Figure 5A, we selected a shCXCL16 cell clone with 80%
reduction in CXCL16 mRNA expression compared to GL261
cells. GL261 or shCXCL16 cells were implanted into the brain
of adult wt mice and 17 days after implantation mice were
sacrificed for tumor volume analysis (Figure 5B). As reported
in Figure 5C, mice injected with shCXCL16 cells revealed a
significant reduction (67%) in tumor volume compared to mice
injected with GL261 (3.3 ± 0.40 mm3 shCXCL16 vs. 9.6 ± 0.67
mm3 GL261) (n= 4; p< 0.001; Student’s t-test). Glioma-bearing
mice were also injected with BrdU 4h before animal sacrifice:
analysis of BrdU incorporation in tumor cells (Figure 5D)
revealed a significant reduction in BrdU+ cells in mice implanted
with shCXCL16 cells (0.45 ± 0.02% of tumor area), compared to
mice implanted with GL261 cells (0.8 ± 0.15% of tumor area)
(n = 3; p < 0.05; Student’s t-test). In addition (Figure 5E) we
found that mice injected with tumor cells silenced for CXCL16
presented a reduced number of glioma cells that migrate and
invade the surrounding brain tissue (12.16 ± 0.82 cells for brain
slice) compared to mice injected with GL261 (24.85 ± 1.49 cells
for brain slice) (n= 3, p< 0.05; Student’s t-test). To exclude that
differences observed in vivo between tumor volume in GL261
and shCXCL16-GL261 bearing mice might be due to clonal
differences between cells rather than to the CXCL16 silencing, we
checked for the expression of markers involved in tumor immune
recognition (specifically MHC class I, CD1 and PD-L1) as well
as tumor cell migration and invasion (CD44). Flow cytometry
analysis revealed no differences in the expression of all these
markers (Supplementary Figure 1). All these data confirm that
CXCL16 released by glioma cells concurs to tumor progression,
and promotes tumor cell proliferation.
Effects of CXCL16/CXCR6 Axis in Patient’s
Derived GBM Cells
To investigate whether CXCL16/CXCR6 also modulates cell
migration, invasion and proliferation in human GBM, we
isolated tumor cells from patient’s derived biopsies (GBM 13, 19,
40, 45) and analyzed their expression of CXCL16 and CXCR6 by
RT-qPCR. We first compared the expression level of cxcl16 and
cxcr6 mRNAs in whole patient’s tissue, and in the corresponding
isolated tumor cells. RNAs from primary human T-cells and a
fibroblasts were used as positive controls for cxcr6 and cxcl16
expression, respectively. All the examined tissues express high
levels of cxcl16 and cxcr6, compared to normal brain tissues (see
Figure 2A); however, the corresponding primary cells, even if
cultured for only few passages (from 1 to 3), showed a strong
reduction in their expression level (Figure 6A). This reduction
could be due to a culture-dependent variation in the expression
level in tumor cells, but we cannot exclude that the differences
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FIGURE 4 | Biological effects of CXCL16/CXCR6 axis on mouse glioma cells. (A) Left panel, chemotactic assay (24 h) of GL261 cells in the absence (C) or presence
of different doses of CXCL16. Data are expressed as percentage of cell migration toward CXCL16 vs. control. Central panel, invasion assay of GL261 cells in
(Continued)
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FIGURE 4 | the absence (C) or presence of different CXCL16 concentrations (1, 10 nM, 48 h). Data are expressed as percentage of cell invasion in CXCL16 stimulated
cells vs. control. Right panel, expression analysis of mmp2, mmp9 metalloproteinases mRNAs by RT-qPCR in GL261 cells not stimulated (vehicle), or stimulated with
CXCL16 (10 nM, 24 h). For each gene data are expressed as specific mRNA fold increase in CXCL16 treated cells normalized to specific mRNA expression in vehicle;
(B) Left panel, growth curve (0, 24, 48 h) of GL261 cells unstimulaed (C) or stimulated with CXCL16 (10 nM); data are expressed as MTT conversion optical density;
middle panel, BrdU incorporation assay on GL261 stimulated with CXCL16 (10 nM, 4 h), or not (C). Data are expressed as number of BrdU+ cells (black or gray bars)
within total counted cells (white bar); Right panel, representative images (scale bar = 20µm) of BrdU incorporation in GL261 cells unstimulated or stimulated with
CXCL16 (BrdU, red signal; Hoechst, blue signal); (C) RT-PCR for cxcr6 and actin mRNAs expression in GL261 shCXCR6 cells induced or not with IPTG (+/–IPTG);
(D) Chemotactic assay of GL261shCXCR6 induced or not with IPTG, not stimulated (C) and stimulated with CXCL16 (10 nM; 24 h); data are expressed as percentage
of cell migration toward CXCL16 vs. control; (E) Growth curve (0, 24, 48, 72, 96 h) of GL261shCXCR6 cells induced or not with IPTG (+/–IPTG); data are expressed
as MTT conversion optical density; (F) (left) representative scheme of GL261shCXCR6 cells transplantation in wt mice; (right) bar histogram of the mean (± s.e.m.) of
tumor volume in shCXCR6-IPTG or shCXCR6+IPTG treated mice, and representative hematoxylin-eosin stained coronal brain sections of glioma bearing mice;
(G) BrdU proliferation analysis in mice transplanted with GL261shCXCR6 cells induced or not with IPTG. (Top) representative images (scale bar = 20µm) of
proliferating BrdU+ cells (red) within tumor area; (bottom) bar histograms of immunofluorescence analysis of BrdU+ cells; data are expressed as % of BrdU+ staining
per tumor area. (H) Analysis of glioma cells invasion of surrounding brain tissue in mice injected with GL261shCXCR6 treated or not with IPTG. (Top), Representative
coronal brain sections stained with hematoxylin/eosin. Black arrows indicate glioma cells invading the brain parenchyma beyond the main tumor border (dashed line)
for more than 150µm. Bottom, bar histogram of the number of glioma invading cells. Statistical analysis: Data are expressed as the mean number (± s.e.m.) (A) left
panel n = 3 in triplicate, *p < 0.05, one-way ANOVA followed by Holm–Sidak post-hoc test; right panel n = 3, *p < 0.05, one-way ANOVA followed by Holm–Sidak
post-hoc test; (B) left panel n = 3 six-replicates, *p < 0.05, one-Way ANOVA followed by Student-Newman-Keuls Method; central panel n = 3, *p < 0.05, Student’s
t-test; (D) n = 4 in duplicate, *p < 0.05, two-way ANOVA followed by Holm–Sidak post-hoc test; (E) n = 4 in quadruplicates, *p < 0.05, one-Way ANOVA followed by
Student-Newman-Keuls Method; (F) n = 5, *p < 0.05, Student’s t-test); (G) n = 3, *p < 0.05, Student’s t-test; (H) n = 3–4, *p < 0.05, Student’s t-test.
observed are due to the selection of specific cell subpopulation
(or the elimination of infiltrating cells in the tumor tissue) during
the cell culture procedures. By flow cytometry analysis, using
specific human CXCR6 PE-conjugated antibody, we confirmed
the expression of membrane CXCR6 protein in primary GBM19
and GBM45 cells (Figure 6B). As reported in Figure 6C, primary
GBM19 and GBM45, cells responded to CXCL16 stimulation
(10 nM, 4 h) increasing their chemotactic index compared to
unstimulated cells (control), thus suggesting the expression of
functional CXCR6 (n = 4, p < 0.05; One way ANOVA followed
by Holm–Sidak post-hoc test). Since it is known that CXCL12 is
able to induce migration of GBM cells (36) and GBM19 and 45
cells do express CXCR4 (data not shown), CXCL12 stimulation
was used as positive control of migratory activity.
GBM19 cells were also used to investigate CXCL16-induced
cell invasion trough matrigel substrate (CXCL16 10 nM, 24 h)
and cell proliferation (CXCL16 10 nM, 24, 48, 72 h). As shown
in Figure 6D, upon stimulation with CXCL16, there was a
significant increase in cell invasion (left panel; n = 3, p < 0.05;
Student’s t-test), and in cell proliferation (right panel; n = 3
experiments in five replicates, p < 0.05; Student’s t-test)
compared to un-stimulated cells (control). All these data indicate
that activation of CXCL16/CXCR6 axis in human primary GBM
cells is able to promote tumor cell proliferation, migration
and invasion. To further support our data, we used cBioportal
Database to look at a possible correlation between patient
survival and CXCR6 expression in glioma tumor. We first
explored the alteration in cxcr6 gene in a merged cohort of
low grade glioma (LGG) and GBM (TCGA, Cell 2016) and
found a significant increase in patient months survival associated
with cxcr6 deletion (median months survival 130.7 vs. 20.6 in
normal cases, Log rank Test P-value 0.0339); we than looked
at cxcr6 mRNA expression data in a cohort of Glioblastoma
(TCGA, Cell 2013) and found a significant decrease in months
survival associated with cxcr6 mRNA overexpression (median
months survival 5.2 vs. 14 in normal cases, Log rank Test P-value
0.00417), Supplementary Figure 2.
DISCUSSION
Communication among cells in the brain parenchyma, including
neurons, astrocytes and microglia, is determinant to maintain
brain homeostasis. The identification of key players in the cellular
cross-talk within the brain, and their alterations in pathological
conditions, can be useful to develop specific tools to limit brain
damage.
In this paper we report for the first time that: (i) CXCL16
drives microglia toward an anti-inflammatory phenotype, able
to counteract inflammatory conditions “in vitro”; (ii) CXCL16
released by glioma cells drives GAMs polarization toward an
anti-inflammatory phenotype which is determinant to promote
glioma progression; (iii) CXCL16 released by tumor cells
contributes to glioma cell proliferation, migration, and invasion
of brain parenchyma.
Recently we reported that CXCL16, acting on astrocytes,
drives neuroprotective effects in brain ischemia, counteracting
glutamate excitotoxic damage (11, 12). Besides glutamate-
excitotoxicity, also neuroinflammation is a common feature
to many chronic or acute neurodegenerative disorders,
including brain ischemia. Following acute brain damages,
microglia cells at the site of injury produce anti-inflammatory
cytokines, scavenger receptors, and trophic factors thus
promoting restorative processes. However, later on, microglia
acquire a pro-inflammatory phenotype releasing pro-
inflammatory cytokines, chemokines, and inducible nitric
oxide synthase, all involved in the exacerbation of brain damage
(37, 38).
In this paper we report that CXCL16 modulates the
inflammatory phenotype of microglia in vitro: in particular, we
found that CXCL16 per se is able to drive microglia toward
an anti-inflammatory phenotype and that, in the context of
an inflammatory microenvironment (LPS and IFNγ), CXCL16
can contrast the acquisition of a pro-inflammatory phenotype.
Considering these data, we speculate that, in addition to limit
neuronal damage, counteracting excitotoxicity, the release of
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FIGURE 5 | CXCL16 released by glioma cells acts promoting tumor proliferation in vivo. (A) RT-PCR for cxcl16 and actin mRNAs expression in GL261 and shCXCL16
cells; (B) representative scheme of GL261 and shCXCL16 cells transplantation in wt mice; (C) bar histogram of tumor volume in GL261 or shCXCL16 cells bearing
mice, and representative hematoxylin-eosin stained coronal brain sections; (D) BrdU proliferation analysis in mice bearing GL261 or shCXCL16 cells. Left panel, bar
histograms of immunofluorescence analysis of BrdU+ cells; data are expressed as % of BrdU+ staining per tumor area; right panel, representative images (scale
bar = 20µm) of proliferating BrdU+ cells (red) within tumor area; (E) Analysis of glioma cells invasion of surrounding brain tissue in mice injected with
GL261shCXCL16 or GL261. Representative coronal brain sections stained with hematoxylin/eosin. Black arrows indicate glioma cells invading the brain parenchyma
beyond the main tumor border (dashed line) for more than 150µm. Right, bar histogram of the number of glioma invading cells. Statistical analysis: Data are
expressed as the mean (± s.e.m.) (C,D) n = 4, *p < 0.05, **p < 0.001, Student’s t-test; (E) n = 3, *p < 0.05, Student’s t-test.
CXCL16 in response to ischemic insult (12) might also trigger
neuroprotection by limiting neuroinflammation.
The same microglia phenotype triggers different effects on
brain homeostasis, in a context-dependent way. During the first
phase of glioma development, microglia reacts to counteract
tumor growth, phagocytizing tumor cells and activating
pro-inflammatory T-cell immune response; at later stages,
glioma-released factors produce chronic stimuli, contributing
to the establishment of a pro-tumoral microenvironment, also
switching GAMs toward an anti-inflammatory/pro-tumor
phenotype (2, 32, 34, 39). In line with what already reported
(40), we found that CXCL16 is over-expressed in human GBM
tissues obtained from patients and demonstrated, in vitro, that
CXCL16 released by glioma cells acts as a mediator for microglia
polarization. We report that neutralization of soluble CXCL16
in GCM results in a strong reduction in the expression of
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FIGURE 6 | Biological effects of CXCL16/CXCR6 axis on primary human
glioblastoma cells.(A) cxcl16 and cxcr6 mRNAs expression in human GBM
tissues (black and white circles), in human primary GBM cells derived from the
same tissues and in human primary T cells and fibroblasts (black and white
triangles) determined by RT-qPCR; (B) CXCR6 surface expression on primary
GBM19 and GBM45 as evaluated by flow cytometry. Black and gray lines
represent CXCR6 staining and isotype control, respectively; (C) Chemotaxis
assay of human primary glioblastoma cells: GBM19 and GBM45, toward
CXCL16 (10 nM, 4 h), CXCL12 (50 nM, 4 h) and vehicle (C). Data are expressed
as percentage of cell migration vs. control; (D) Left panel, matrigel invasion
assay on human GBM19, toward CXCL16 (10 nm, 24 h) and vehicle (C). Data
are expressed as percentage of cell invasion vs. control (n = 3, p < 0.05,
Student’s t-test); right panel, proliferation assay of GBM19 upon stimulation
with CXCL16 (10 nM) at different time points (0, 24, 48, and 72 h), data are
expressed as MTT conversion optical density. Statistical analysis: Data are
expressed as the mean (± s.e.m.) (C) n = 4, *p < 0.05, one-way ANOVA
followed by Holm–Sidak post-hoc test; (D) left panel n = 3, *p < 0.05,
Student’s t-test; right panel n = 3 in five replicates, *p < 0.05, Student’s t-test.
anti-inflammatory genes in microglia (arg-1, chil3, retnla, cd163),
and in a significant increase of pro-inflammatory genes (nos2,
il-1b, cd86, tnfa), compared to microglia cells exposed to control
GCM, suggesting that soluble CXCL16 released by tumor cells
promotes microglia pro-tumor phenotype.
Using cxcr6ko mice, we confirmed the crucial role of the
CXCL16/CXCR6 axis in the establishment of a pro-tumor
microenvironment. These mice, transplanted with GL261 cells,
have a strong reduction in tumor volume and a significant
increase in mice survival when compared to wt animals.
Moreover, analysis of Iba1 and CD68 immune-reactivity within
the tumor mass reveals a different activation state of GAMs in
cxcr6ko mice, indicating an effect of CXCR6 signaling on GAMs
activation. Accordingly, the analysis of CD11b+ cells derived
from the brain hemispheres of tumor injected mice, confirms
the role of CXCL16 signaling in determining GAMs polarization:
indeed, the strong up-regulation of anti-inflammatory genes
observed in the brain of wt animals did not occurred in cxcr6ko
mice. Other chemokines released by glioma cells, such as CCL2,
have been reported to play a role in the recruitment of GAMs
within the tumor mass, but do not contribute to their phenotypic
changes (18). Thus, CXCL16 is the first chemokine released by
glioma cells that has been proven to drive the interplay with
GAMs to acquire a phenotype that supports tumor growth.
GBM are characterized by extensive proliferation and
dissemination of the tumor cells within the brain that hinders
complete surgical resection (41, 42). The high invasion ability of
GBM is due to multiple autocrine motility-enhancing signaling
systems, and to distinct signals derived from non-tumor
infiltrating and stromal cells.
For the first time we demonstrated that CXCL16/CXCR6 axis
plays a role in promoting glioma growth, directly acting on
tumor cells. Specifically, we demonstrated that: (i) GL261 cells
express both CXCL16 and CXCR6; (ii) stimulation with CXCL16
promotes GL261cell migration, invasion, and proliferation; (iii)
the silencing of CXCR6 on glioma cells reduces their proliferation
rate andmigration ability; (iv) in vivo, transplantation of CXCR6-
silenced GL261 cells in wt mice leads to a reduced tumor cell
proliferation and infiltration and tumor volume compared to
mice injected with not silenced glioma cells.
The absence of CXCR6 on glioma cells, but not on other cells
of tumor microenvironment, reduces but does not block tumor
development, suggesting that other signals are important for
tumor progression, and again confirming that CXCL16/CXCR6
signaling acts also on cells of the tumor microenvironment.
The hypothesis that CXCL16 released from tumor cells acts
in an autocrine/paracrine way to promote tumor progression
is further confirmed by the significant reduction in tumor
volume, proliferation, and infiltration in mice bearing glioma
cells silenced for CXCL16. We have previously shown that
GL261/cd133+ cells grafted in mice resulted in a higher tumor
volume compared to mice grafted with GL261 (43), we now
report that within glioma, GL261/cd133+ cells do present
a higher cxcr6 mRNA expression compared to GL261, thus
suggesting that autocrine CXCL16 signaling plays also a role in
cancer stem cells.
The role of CXCR6 in human glioma cells is controversial:
high expression of CXCL16 has been reported in several
human GBM cell lines, as well as in human glioma tissues
(TCGA database), in contrast to a very low, sometimes almost
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undetectable, expression of CXCR6 (21). Moreover, by in situ
hybridization, it has been shown that CXCR6 is expressed in
glioma only on a small population of cells that are positive for
markers of embryonic or neural stem cells (21). Considering the
very low expression level of cxcr6 in GBM cells, as measured by
real-time PCR, authors speculated that CXCR6 could not play a
role in glioma cell biology (22). While we confirm that primary
human GBM cells from patients express low levels of cxcr6 and
cxcl16, we report that the original GBM tissues, acutely dissected
from patients, over-express both cxcl16 and cxcr6, compared to
human control brain tissues. In spite of the low expression level
of cxcr6, we demonstrate that the human primary GBM cells do
express CXCR6 protein (as revealed by flow cytometry analysis)
and respond to CXCL16 stimulation, modulating migration,
invasion, and proliferation, thus suggesting an important activity
of CXCL16 in glioma cell biology also in humans. According
to Hattermann et al. (22), soluble CXCL16 might act with
an “inverse signaling” mechanism that is independent by its
receptor, and dependent by the transmembrane form of the
chemokine expressed by cells; however, we demonstrated that
the direct effects of the soluble CXCL16 on GL261 cells, in
terms of proliferation, migration and invasion, are prevented
when these cells are silenced for the CXCR6 receptor, but still
expressing transmembrane CXCL16, both in vitro and in vivo
(Figures 4D–H), highlighting an important activity of CXCR6 at
least in these cells. In analogy to what has been recently reported
for another GBM-derivedmolecule, osteopontin, which regulates
glioma cell invasiveness and tumor growth (44) and the pro-
tumorigenic reprogramming of microglia (45), we demonstrate
that soluble CXCL16 released by glioma cells drives GBM growth
directly promoting tumor cell proliferation, invasion, and acting
on GAMs establishing a pro-tumor microenvironment. We also
prove that human infiltrating GAMs do express cxcr6, further
supporting the idea that also in human, CXCL16 released by
tumor cells, might act on these cells promoting a pro-tumor
microenvironment.
For the first time we show that CXCL16/CXCR6 axis plays
an important role in driving the cross-talk among cells within
the brain and microglia, as well as infiltrating macrophages,
triggering a phenotype that, depending on environmental
cues, can be either neuroprotective or detrimental. These data
highlight the potential use of CXCL16 as pharmacological
tool to augment the anti-inflammatory cellular response and
to restrain inflammatory stimuli. Moreover, since disruption
of CXCL16 signaling counteracts glioma progression limiting
cell proliferation and migration but also microglia pro-
tumor polarization, a multi-target therapy including the
use of a CXCR6 antagonist, together with drugs approved
by Food and Drug Administration (FDA) and currently
used to treat GBM patients (such as Temozolomide or
checkpoint inhibitors that target programmed cell death
protein 1,PD-1) could be potentially considered in the
future.
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